清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19

医学 重症监护室 肝素 随机对照试验 加药 凝血病 随机化 低分子肝素 肾功能 败血症 内科学 麻醉
作者
Alex C. Spyropoulos,Mark Goldin,Dimitrios Giannis,Wassim Diab,Janice Wang,Sameer Khanijo,Andrea Mignatti,Eugenia Gianos,Marc Cohen,Gulru Sharifova,Jeet Lund,Alfonso Tafur,Paul A. Lewis,Kevin P. Cohoon,Husneara Rahman,Cristina Sison,Martin Lesser,Kanta Ochani,Nirav Agrawal,Judith Hsia,Victoria E. Anderson,Marc P. Bonaca,Jonathan L. Halperin,Jeffrey I. Weitz,Lori Ohanesian,Michelle Glater,Christopher C.K. Ho,Annamaria Iakovou,Daniel Ying,Manile Dastagir,Alex Convissar,Seerat Aujla,Elizabeth Mathew,Vani Thiyagarajan,Tricia Lewis,Luis Gruberg,Paul Maccaro,Dana Kuziw,Bhumi Pandhi,George Surguladze,Ashley M. Eapen,A. Pantea,Phyllis Suen,John P. Flynt,Michael Krzyzak,Kamal Sharma,Amanda Steadham,Sherry McLean,Karen Herring,Karen Maroney,Kambiz Zorriasateyn,B. Vargas,Marisa Durante,Ujala Bhokary,Linda Pierchala,Elizabeth A. Fisher,Debi L. Oxenberg,Alison Sabados,Omair A. Chaudhary,Shelley Schultz,S. Cotey,Connie N. Hess,Hope Cruse,Daniel Uy,Sunita Sharma,Kevin Molina,Daliya Jagat,Bandyopadhyay Dehali
出处
期刊:JAMA Internal Medicine [American Medical Association]
卷期号:181 (12): 1612-1612 被引量:330
标识
DOI:10.1001/jamainternmed.2021.6203
摘要

Hospitalized patients with COVID-19 are at risk for venous and arterial thromboembolism and death. Optimal thromboprophylaxis dosing in high-risk patients is unknown.To evaluate the effects of therapeutic-dose low-molecular-weight heparin (LMWH) vs institutional standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19.The HEP-COVID multicenter randomized clinical trial recruited hospitalized adult patients with COVID-19 with D-dimer levels more than 4 times the upper limit of normal or sepsis-induced coagulopathy score of 4 or greater from May 8, 2020, through May 14, 2021, at 12 academic centers in the US.Patients were randomized to institutional standard prophylactic or intermediate-dose LMWH or unfractionated heparin vs therapeutic-dose enoxaparin, 1 mg/kg subcutaneous, twice daily if creatinine clearance was 30 mL/min/1.73 m2 or greater (0.5 mg/kg twice daily if creatinine clearance was 15-29 mL/min/1.73 m2) throughout hospitalization. Patients were stratified at the time of randomization based on intensive care unit (ICU) or non-ICU status.The primary efficacy outcome was venous thromboembolism (VTE), arterial thromboembolism (ATE), or death from any cause, and the principal safety outcome was major bleeding at 30 ± 2 days. Data were collected and adjudicated locally by blinded investigators via imaging, laboratory, and health record data.Of 257 patients randomized, 253 were included in the analysis (mean [SD] age, 66.7 [14.0] years; men, 136 [53.8%]; women, 117 [46.2%]); 249 patients (98.4%) met inclusion criteria based on D-dimer elevation and 83 patients (32.8%) were stratified as ICU-level care. There were 124 patients (49%) in the standard-dose vs 129 patients (51%) in the therapeutic-dose group. The primary efficacy outcome was met in 52 of 124 patients (41.9%) (28.2% VTE, 3.2% ATE, 25.0% death) with standard-dose heparins vs 37 of 129 patients (28.7%) (11.7% VTE, 3.2% ATE, 19.4% death) with therapeutic-dose LMWH (relative risk [RR], 0.68; 95% CI, 0.49-0.96; P = .03), including a reduction in thromboembolism (29.0% vs 10.9%; RR, 0.37; 95% CI, 0.21-0.66; P < .001). The incidence of major bleeding was 1.6% with standard-dose vs 4.7% with therapeutic-dose heparins (RR, 2.88; 95% CI, 0.59-14.02; P = .17). The primary efficacy outcome was reduced in non-ICU patients (36.1% vs 16.7%; RR, 0.46; 95% CI, 0.27-0.81; P = .004) but not ICU patients (55.3% vs 51.1%; RR, 0.92; 95% CI, 0.62-1.39; P = .71).In this randomized clinical trial, therapeutic-dose LMWH reduced major thromboembolism and death compared with institutional standard heparin thromboprophylaxis among inpatients with COVID-19 with very elevated D-dimer levels. The treatment effect was not seen in ICU patients.ClinicalTrials.gov Identifier: NCT04401293.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
46464发布了新的文献求助10
3秒前
6秒前
ZZ发布了新的文献求助10
11秒前
Eri_SCI完成签到 ,获得积分10
29秒前
Bazinga完成签到,获得积分10
2分钟前
顾矜应助lin.xy采纳,获得10
2分钟前
4分钟前
lin.xy发布了新的文献求助10
4分钟前
lin.xy完成签到,获得积分10
4分钟前
xaopng完成签到,获得积分10
5分钟前
5分钟前
kryzhang发布了新的文献求助10
5分钟前
tingyeh完成签到,获得积分10
6分钟前
宇文傲龙完成签到 ,获得积分10
7分钟前
Eatanicecube完成签到,获得积分10
7分钟前
Richard完成签到 ,获得积分10
8分钟前
爱听歌的书雁完成签到,获得积分10
10分钟前
木子倪发布了新的文献求助30
11分钟前
12分钟前
木子倪发布了新的文献求助30
12分钟前
Owen应助科研通管家采纳,获得10
13分钟前
糊涂的青烟完成签到 ,获得积分10
14分钟前
vitamin完成签到 ,获得积分10
14分钟前
tinner完成签到,获得积分10
14分钟前
可爱的函函应助sunny采纳,获得10
15分钟前
紫熊发布了新的文献求助30
17分钟前
18分钟前
18分钟前
18分钟前
赘婿应助小小怪很聪明采纳,获得10
18分钟前
511完成签到 ,获得积分10
18分钟前
肆肆完成签到,获得积分10
19分钟前
紫熊完成签到,获得积分10
19分钟前
19分钟前
sunny发布了新的文献求助10
19分钟前
20分钟前
sunny完成签到,获得积分10
20分钟前
20分钟前
21分钟前
zsmj23完成签到 ,获得积分0
21分钟前
高分求助中
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Gerard de Lairesse : an artist between stage and studio 500
Digging and Dealing in Eighteenth-Century Rome 500
Queer Politics in Times of New Authoritarianisms: Popular Culture in South Asia 500
Livre et militantisme : La Cité éditeur 1958-1967 500
Retention of title in secured transactions law from a creditor's perspective: A comparative analysis of selected (non-)functional approaches 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3063160
求助须知:如何正确求助?哪些是违规求助? 2717940
关于积分的说明 7456727
捐赠科研通 2364292
什么是DOI,文献DOI怎么找? 1253382
科研通“疑难数据库(出版商)”最低求助积分说明 608564
版权声明 596606